A longitudinal study of an individual patient developing neutralizing antibodies against HIV-1 (targeting the V1V2 region of gp120) reveals how such neutralizing antibodies develop and evolve over time, providing important insights relevant to vaccine development.
- Nicole A. Doria-Rose
- Chaim A. Schramm
- John R. Mascola